Annette Hänel

984 total citations
13 papers, 639 citations indexed

About

Annette Hänel is a scholar working on Pathology and Forensic Medicine, Hematology and Genetics. According to data from OpenAlex, Annette Hänel has authored 13 papers receiving a total of 639 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 6 papers in Hematology and 5 papers in Genetics. Recurrent topics in Annette Hänel's work include Lymphoma Diagnosis and Treatment (7 papers), Lung Cancer Treatments and Mutations (4 papers) and Acute Myeloid Leukemia Research (3 papers). Annette Hänel is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Lung Cancer Treatments and Mutations (4 papers) and Acute Myeloid Leukemia Research (3 papers). Annette Hänel collaborates with scholars based in Germany, United Kingdom and United States. Annette Hänel's co-authors include Bernd Metzner, Christiane Pott, H. Wandt, Wolfgang Hiddemann, Roland Repp, Roswitha Forstpointner, Frank Hartmann, Michael Unterhalt, Thomas Lehmann and Martin Dreyling and has published in prestigious journals such as Blood, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Annette Hänel

12 papers receiving 627 citations

Peers

Countries citing papers authored by Annette Hänel

Since Specialization

Citations

This map shows the geographic impact of Annette Hänel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annette Hänel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annette Hänel more than expected).

Fields of papers citing papers by Annette Hänel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annette Hänel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annette Hänel. The network helps show where Annette Hänel may publish in the future.

Co-authorship network of co-authors of Annette Hänel

This figure shows the co-authorship network connecting the top 25 collaborators of Annette Hänel. A scholar is included among the top collaborators of Annette Hänel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annette Hänel. Annette Hänel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma 2024 ·Journal of Cancer Research and Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Regina Herbst, Annette Hänel, Anke Morgner, Stefan Ibach, Stephan Fricke, Mathias Hänel	0
2	Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG‐HD2 trial 2016 ·British Journal of Haematology ·K. Elias, Axel Benner, Uta Bertsch, Peter Brossart, Annette Hänel, Volker Kunzmann, Ralph Naumann, Kai Neben, Gerlinde Egerer, Anthony D. Ho, Jens Hillengaß, Marc S. Raab, Andreas Neubauer, (unknown), Yon‐Dschun Ko, Norma Peter, Christof Scheid, Hartmut Goldschmidt	47
3	Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL) 2015 ·Annals of Oncology ·Andreas Thiel, Johannes Schetelig, Wolfram Pönisch, K. Schäfer-Eckart, Walter E. Aulitzky, N. Peter, Antina Schulze, Georg Maschmeyer, (unknown), Regina Herbst, Annette Hänel, Anke Morgner, Frank Kroschinsky, Martin Bornhäuser, Thoralf Lange, Mathias Wilhelm, Dietger Niederwieser, G. Ehninger, F. Fiedler, Mathias Hänel	7
4	Identification of a MYO18A‐PDGFRB fusion gene in an eosinophilia‐associated atypical myeloproliferative neoplasm with a t(5;17)(q33‐34;q11.2) 2008 ·Genes Chromosomes and Cancer ·Christoph Walz, Claudia Haferlach, Annette Hänel, Georgia Metzgeroth, Philipp Erben, (unknown), Andreas Hochhaus, Nicholas C.P. Cross, Andreas Reiter	30
5	Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) 2006 ·Blood ·Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling, (unknown), Roland Repp, H. Wandt, Christiane Pott, John F. Seymour, Bernd Metzner, Annette Hänel, Thomas Lehmann, Frank Hartmann, Hermann Einsele, Wolfgang Hiddemann	336
6	Activity of sirolimus in patients with myelodysplastic syndrome – results of a pilot study 2005 ·British Journal of Haematology ·Uwe Platzbecker, Michael Haase, Regina Herbst, Annette Hänel, (unknown), Christian Thiede, Brigitte Mohr, Eberhard Schleyer, (unknown), Matthias Orth, Mathias Hänel, Gerhard Ehninger, Martin Bornhäuser	30
7	Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma 2004 ·British Journal of Cancer ·Ralph Naumann, Bettina Beuthien‐Baumann, (unknown), Jan Schulze, Annette Hänel, Jan Bredow, G Kühnel, J. Kropp, Mathias Hänel, Michael Laniado, J. Kotzerke, Gerhard Ehninger	106
8	Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma 2002 ·Annals of Hematology ·Mathias Hänel, Nicolaus Kröger, (unknown), Martin Bornhäuser, William Krüger, Frank Kroschinsky, Annette Hänel, Bernd Metzner, Josef Birkmann, Bernd Schmid, M. Hoffknecht, F. Fiedler, Gerhard Ehninger, AR Zander	35
9	Rituximab zur Remissionsinduktion bei rezidivierten und refraktären indolenten Lymphomen und Mantelzell-Lymphomen 2002 ·DMW - Deutsche Medizinische Wochenschrift ·Roswitha Forstpointner, Annette Hänel, Roland Repp, Sandra Hermann, Bernd Metzner, Christiane Pott, Franz Hartmann, Frank Rothmann, (unknown), H. Wandt, Michael Unterhalt, Wolfgang Hiddemann	6
10	[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]. 2002 ·DMW - Deutsche Medizinische Wochenschrift ·Roswitha Forstpointner, Annette Hänel, Roland Repp, Sandra Hermann, Bernd Metzner, Christiane Pott, Frank Hartmann, Frank Rothmann, (unknown), H. Wandt, Michael Unterhalt, W. Hiddemann	7
11	Mito-FLAG as Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia 2001 ·Oncology Research and Treatment ·Mathias Hänel, (unknown), Annette Hänel, Regina Herbst, Anke Morgner, Sabine Neser, (unknown), (unknown), Gerhard Ehninger, F. Fiedler	22
12	Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma 2001 ·Journal of Cancer Research and Clinical Oncology ·Mathias Hänel, Nicolaus Kröger, Frank Kroschinsky, Josef Birkmann, Annette Hänel, Regina Herbst, Ralph Naumann, (unknown), Gerhard Ehninger, A Zander, F. Fiedler	4
13	ASHAP - an effective salvage therapy for recurrent and refractory malignant lymphomas 2000 ·Annals of Hematology ·Mathias Hänel, Nicolaus Kröger, M. Hoffknecht, S. Peters, Bernd Metzner, F. Fiedler, D. Braumann, (unknown), H. J. Illiger, Annette Hänel, William Krüger, W. Zeller, H.J. Weh, D Hossfeld, A Zander	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact